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Abstract: Spasticity is characterized by velocity-dependent increase in tonic stretch reflexes
and tendon jerks. Many people affected by spasticity receive late treatment, or no treatment,
which greatly reduces the potential to regain full motor control and restore function. There is
much to consider before determining treatment for people with spasticity. Treatment of pediatric patients increases the complexity, because of the substantial difference between adult and
pediatric spasticity. Proper patient evaluation, utilization of scales and measures, and obtaining
patient and caregiver history is vital in determining optimal spasticity treatment. Further, taking
into consideration the limitations and desires of individuals serve as a guide to best management.
We have grouped contributing factors into the IDAHO Criteria to elucidate a multidisciplinary
approach, which considers a person’s complete field of experience. This model is applied to
goal setting, and recognizes the importance of a spasticity management team, comprising the
treatment subject, his/her family, the environment, and a supportive, well-informed medical
staff. The criteria take into account the complexity associated with diagnosing and treating
spasticity, with the ultimate goal of improved function.
Keywords: spasticity treatment modalities, pediatric spasticity management, optimal
management for spasticity
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Spasticity is clinically described as a motor disorder, characterized by a velocitydependent increase in tonic stretch reflexes and exaggerated tendon jerks, resulting
from hyper-excitability of the stretch reflex, as one component of the upper motor
neuron syndrome. Many diseases and injuries affecting the central nervous system
(CNS) result in impairment of neuromuscular function, manifested as spasticity.
Cerebral palsy (CP), multiple sclerosis (MS), traumatic brain injury (TBI), spinal cord
injury (SCI), and cerebrovascular accident (CVA) are commonly encountered conditions that result in this neuromuscular dysfunction. In people with spasticity, neural
impulses misfire, resulting in symptomatology that can affect both the upper and
lower extremities.
An estimated 500,000 people in the United States, and twelve million people
worldwide, experience spasticity.1 Yet, many of those affected are neglected, or treated
late for their spasticity, and relegated to salvage treatment of end effects on the musculoskeletal system. This approach leaves little hope for regaining full motor control
and restoring pre-disease or pre-injury function.
When treating spasticity, it is imperative to understand its functional effects, and
recognize that spasticity is not always deemed detrimental by the affected person,
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or their caregiver. In its mildest form, spasticity may substitute
for muscular weakness, aid in the preservation of muscle mass,
and decrease the prevalence of deep venous thrombosis.2
However, spasticity is damaging in its more severe forms.
Spasticity causes imbalanced muscle forces that act upon bones,
joints, and the muscles themselves. This imbalance results in
bony angular and torsional deformities, subluxation/dislocation
of joints, capsular contractions, and muscle shortening. These
findings were substantiated by Mercer Rang, who studied
spastic mice that had developed restricted joint range, restrictive
muscle excursion, and bony degeneration.3 These findings
are considered to be the musculoskeletal ramifications of
spasticity. Other skeletal ramifications include pain, casting
or bracing challenges, skin complications, and challenges
for fracture management.4 Additionally, spasticity impacts
children differently than adults. Spasticity during growth
compounds the soft tissue ramifications of increased tone. This
is highlighted by excessive muscle shortening and abnormal
bone growth, as a result of the imbalanced muscle forces acting
upon growth plates.5,6
Many aspects are considered before deciding on treatment options for individuals with spasticity. These aspects
not only include present-time quality of life, comfort, and
function, but also future impairments, which may present
as the result of growth, or expected decline in strength with
age. Assessment of these aspects includes the patient’s and
the caregiver’s perspectives.7

Patient evaluation
While it is easily recognized that severe TBI, CVA, and a
variety of neurological disorders can result in spasticity,
the actual diagnosis of spasticity is more complex. The
complexity arises from challenges in distinguishing among
abnormal patterns of muscle tone, such as volitional guarding, contracture, dystonia, paresis, paratonia, and rigidity.4,8–10
Furthermore, other movement disorders may be present in
addition to spasticity. The incidence of these other movement
disorders varies, depending upon the underlying etiology. It
can be very frequent in cerebral palsy, rare following stroke
(3.7%), and nonexistent following spinal cord injury. 11
Establishing the presence of accompanying movement
abnormalities is important, as many of these are unaffected
by traditional treatments for spasticity, and may appear more
prominent when spasticity is reduced. Observation of the
patient during tasks, and in ambulation, can identify these
additional movement disorders by their salient features.12
Video analysis is extremely helpful in diagnosis, and
serves as a useful aid in detecting change following treatment.
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Though formal motion analysis in a gait lab is ideal,
observational analysis with simple video is inexpensive, less
labor- and time-intensive, and is often equally informative.
We highly recommend obtaining video during an initial,
thorough baseline physical therapy visit, when possible.
Many picture archiving and communicating systems store
these videos alongside radiographic studies, making them
readily accessible.
During these initial sessions, passive range of motion
is assessed during different velocities of movement to
measure contracture and degree of spasticity. The Modified
Ashworth Scale (MAS) is the most-utilized scale to measure
spasticity. Since its inception, however, the validity and
reliability of MAS has been challenged. To address issues
with MAS, the Modified Modified Ashworth Scale (MMAS)
was developed. In the revised scale, the ambiguity of the
1+ grade has been omitted, and grade 2 has been redefined.
MMAS ranges from 0–4: 0 = no increase in muscle tone;
1 = slight increase in muscle tone, manifested by a catch
and release, or by minimal resistance at the end of the range
of motion when the affected part(s) is moved in flexion or
extension; 2 = marked increase in muscle tone, manifested
by a catch in the middle range and resistance throughout the
remainder of the range of motion, but the affected part(s) is
easily moved; 3 = considerable increase in muscle tone, with
passive movement being difficult; and 4 = affected part(s)
is rigid in flexion or extension.12 Though MMAS is not currently widely used, studies have supported the reliability of
the scale.13 It allows grades to be more clearly defined, and
provides for better clinical practice.
If appropriate, active motion is assessed for measures
of function, timed functional trials, fatigability and repeatability, and selective motor control. A number of scales
exist, which are used with the appropriate diagnoses and
underlying impairment.14
Though physical examination is a critical component of
patient evaluation, the patient and caregiver history is also
integral to determining optimal treatment for spasticity.
Understanding the limitations that each person experiences
as a result of the spasticity, as well as understanding their
respective desire for tone reduction and strengthening, helps
guide best management. For example, with adults who rely
upon stand-pivot transfers, and depend upon their spasticity
to achieve this task, and who have either a low desire or an
inability to strengthen adequately, intrathecal baclofen may
not be the optimal choice to reduce spasticity. On the other
hand, a very motivated young child, with substantial growth
remaining, and a supportive family, may be an excellent
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candidate for intrathecal baclofen treatment, despite a possible temporary early reduction in function.

Treatment options
Two primary treatment algorithms exist for spasticity management, each dependent upon the magnitude of cognitive
impairment. The ultimate treatment goal in the first group is
to improve care and comfort for those who are significantly
impaired, both physically and mentally, and who reply
upon others for care. Functional improvement becomes
increasingly challenging as cognitive ability declines,
while improving comfort greatly improves quality of life
for both the impacted individual and their caregiver. Most
families and caregivers are satisfied with improved comfort,
increased quality of life, and eased caregiving as outcomes of
this treatment. The benefits of such an approach are widely
documented in the literature.15
For the population who are physically debilitated but
who have lesser degrees of mental impairment, the roles of
spasticity reduction become less clear. The controversies
include:
1. Weighing spasticity reduction against potential loss of
function
2. Spasticity reduction without an associated improvement
in function.
A common belief is that spasticity reduction options that
impact on function should be avoided. This phenomenon is
commonly seen in young individuals with spastic diplegic
cerebral palsy, and in adult stroke or incomplete spinal cordinjured patients who live independently. For example,
caregivers and family members who witness an initial loss
of ambulation or transfer ability following an intrathecal
baclofen trial will often deem it a failure. Though this snapshot of function may be accurate, ignoring the implications
of long-term spasticity may be nearsighted. Though spasticity
may aid in short term preservation of function, it commonly
results in long-term musculoskeletal impairments, such as
joint contractures, muscle shortening, and bony deformity.
Oftentimes, pediatric patients who substitute for weakness
with spasticity will ultimately lose any function gained
from utilizing their increased tone, as their mass increases.16
Therefore, it is important to consider the long-term implications of spasticity, and to weigh it against short-term gains,
to avoid this outcome.
Another controversial issue centers on the prevailing
historical view that spasticity management should lead to
measurable and immediate improved function in order to
be considered an effective treatment. Though it is clearly a
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desirable outcome, there are many other elements that affect
function, making this short- to mid-term goal impossible to
assess. Currently-used scales perform well in measuring different abilities directly or indirectly impacted by increased
tone, but do not address the aforementioned aspects, which
contribute to functional goal attainment, alongside inherent
ability. For example, the Gross Motor Function Classification
System (GMFCS) is an excellent classification of mobility
and ambulatory ability. The GMFCS and similar scales simply describe categories in which the individual resides.17 As
a result, these scales limit assessment of potential through
not taking into account individuals’ characteristics and their
environmental support.
In response to the limitations of predicting outcomes
using current classification systems, assessment tools, and
scales, we devised a concise collection of a small number
of variables, which we have found to influence function
in individuals experiencing spasticity, and developed the
IDAHO Criteria (Figure 1). It is similar in concept to the
World Health Organization’s International Classification
of Functioning, Disability and Health (ICF),18 which is
formidable and rarely used clinically or otherwise.19 The
ICF is exhaustively detailed in compiling factors to measure
health and disability, and serves as a valuable research tool.
The IDAHO Criteria offers a simple alternative schematic
to assist in evaluating an individual’s potential. This model
guides goal setting, and recognizes the importance of
many factors integral to attaining functional improvement;
treatment options are evaluated holistically for optimal
outcomes. Approaches that consider the processes involved
with health care delivery have demonstrated improved patient
and family satisfaction.20,21

Infrastructure

Desire

Opportunity

Hospital
access

Ability

Figure 1 The IDAHO criteria.
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First, we assess the individual’s Infrastructure (I), which
is the supportive environment in which they live. Spastic
individuals who have full-time emotional and physical support have a distinct advantage. Access to essential exercise
equipment and the opportunity to learn proper musclestrengthening techniques are optimal for improving muscle
strength and subsequent function.
Next, we assess the individual’s Desire (D), which pertains to their motivation and courage in generation and pursuit
of stated outcomes. Desire is an especially vital component,
which must be properly addressed in order to confirm that
the person, his/her family members, and medical staff are
all fully aware of the person’s situation, thereby permitting
open communication and establishing realistic goals. It is
imperative to define Desire because, frequently, the person
and his/her family members, prior to consultation with the
physician, may set unreasonable goals regarding spasticity
management; when these exalted goals are not achieved as
imagined, discouragement may develop, and impede the
recovery progress.4 However, through effective communication and establishing practical, realistic goals, improvement
can be facilitated. Appropriately addressing the Desire component can help to avoid discouragement, and regression in
recovery can be avoided.
Ability (A) refers to an individual’s inherent physical
and mental characteristics. This is based on both the level of
impairment and the pre-existing physical state. For example,
irrespective of the severity of spasticity, a person with cognitive impairment cannot be assumed to have the same ability to
improve as a person without deficits. Additionally, selective
motor control greatly enhances one’s ability to strengthen,
following spasticity reduction.
Hospital Access (H) is defined by proximity of the
subject’s residence to professional care services. Hospital
access demonstrates the existence of geographic disparities,
in which location is a leading determinant in whether or
not health care is accessible, along with the ease of access.
Statistics indicate that, in the United States, a quarter of
Hispanics, and a third of African-Americans and American
Indian/Alaskan natives live outside metropolitan areas where
suitable hospitals are located. Consequentially, a large proportion of people do not receive adequate attention and appropriate care, solely due to their location.22 Similarly, in Third
World countries, access to state-of-the-art care is limited. The
Hospital Access component of the criteria encourages the
recognition of location, and the importance of understanding
that location has a significant impact, not only on the person’s
treatment plans but also on proper diagnosis.
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Finally, Opportunity (O) signifies the economic aspect of
access to specialty care and treatment opportunities, which has
the potential to drastically change the treatment directive.23
Research has revealed that ethnic and racial minorities are
statistically shown to have incomes that fall below 200 percent
of the federal poverty level, suggesting that they are more
likely to be uninsured, in comparison to other Americans.
Undoubtedly, this implies that a tremendous disparity in
health care delivery is associated with socioeconomic status,
which must be recognized when performing evaluations.22
Unfortunately, because of health care disparities, those
affected by socioeconomic and geographic disparities are also
affected by disparities in opportunity. Based on their lowincome status, some people are unable to access specialized
physicians at high-quality hospitals. For this reason, their
goals and their treatment routes may not be suitable. Thus,
proper improvement may not be achieved.22
Treatment options are based on the determination of
localized or generalized spasticity, its level of severity, degree
of selective motor control, cognitive function, and the personal needs of the individual. Once these factors have been
analyzed, different modalities of treatment are considered,
including nonpharmaceutical, oral medication, intramuscular
injection, and intrathecal medication.
Nonpharmaceutical methods, which have been utilized
for many decades to manage spasticity, include bracing,
casting, occupational therapy, physiotherapy, and surgery.
Although these methods fail to eliminate the underlying
issue, they do provide support, substitute for weak muscles,
and maintain a range of joint motion, in order to alleviate
the challenges of daily activity.24 While nonpharmaceutical
and nonsurgical options may aid individuals in mobility, the
extent to which they are considered successful in improving
range of motion remains debated. Soft tissue surgical interventions are utilized as well. But surgery does not directly
address spasticity. Surgery should be considered a salvage
method, to optimize outcomes once spasticity has been
adequately treated. This is particularly true in the pediatric
population, wherein repeated lengthening of the musculotendinous unit in a growing child often results in weakening
of muscle. Furthermore, it is the experience of the author
that outcomes achieved by surgery, regardless of the age
when performed, are best maintained by optimal spasticity
management. Selective dorsal rhizotomy (SDR) is another
surgical option for spasticity management. Historically, it
has been reserved for children with spastic diplegia who
have very good strength. A few studies have demonstrated
good long-term outcomes with this method. The challenge in

Degenerative Neurological and Neuromuscular Disease 2012:2

Dovepress

this conclusion is that children with a degree of underlying
ability do well regardless of the management chosen.25–27 In
addition, this surgery is irreversible. Spasticity often returns
with maturity, and secondary deformities occur.28
Traditionally, orally-administered medications have
been the primary and most widely used method of treatment for spasticity. Some commonly used oral medications
include gamma amino butyric acid (GABA) agonists (such
as baclofen and benzodiazepines) and muscle relaxants
(such as dantrolene and α2-adrenergic agonists, including
tizanidine).4,24 Unfortunately, these medications permit shortterm benefits but frequently lead to further complications.
In cases of severe spasticity, oral medications reduce tone
inadequately; the tone reduction achieved fluctuates and does
not provide a steady state of effect.4
Furthermore, the sedating effects of the oral baclofen
dosages required to provide adequate spasticity management commonly interfere with cognitive function and
development.29 In addition to drowsiness, the systemic side
effects of dantrolene and tizanidine must be closely monitored, to avoid hematologic and hepatic damage.
Investigations of focal spasticity have shown that localized interventions are a more successful method of treatment.
Intramuscular injections, which include injections of botulinum toxin, alcohol, and phenol have shown to be more
effective in directly treating the spastic muscle and decreasing
adverse side effects.4
Botulinum toxin is a natural toxin formed from
Clostridium botlinum bacteria. It acts by inhibiting the
release of acetylcholine at the neuromuscular junction, with
high specificity, and has been demonstrated to be safe and
efficacious in treating abnormally increased muscle tone.30,31
Botulinum toxin takes effect two to three days after injection,
and peaks clinically at 4–6 weeks, gradually wearing off
at 3–4 months. This leads to staggered results. Those who
receive the maximum number of injections are relieved, for
various episodes, approximately 4 months out of a year.32
However, in patients with good selective motor control, the
positive results can persist for 6 months or longer. Individuals
with selective motor control of the antagonistic muscles are
ideal candidates for botulinum toxin injections.
A l c o h o l a n d p h e n o l a r e b o t h n o n s e l e c t ive
chemodenervating therapeutic agents, and are less diffusive
than botulinum toxin. They are less costly options, and are
advantageous in their rapid onset and localized potency, but
pose possible risks of soft tissue fibrosis development, as
well as dysesthesia.33 Also, alcohol and phenol are difficult
to inject, requiring perineural placement, or placement near
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the point of motor innervation.23 The effects of phenol are
irreversible, and may reduce contraction during voluntary
movements, produce scarring, granuloma formation, and
edema.24 Additionally, given the shorter duration of effect of
alcohol injections, they are less commonly employed.
Finally, intrathecal baclofen (ITB), approved by the
Food and Drug Administration in 1996, is being used to
treat spasticity. Instead of paralyzing muscle cells, ITB
works as a GABA agonist. GABA is an inhibitory neurotransmitter, which relaxes antagonist muscles (ie, reduces
co-contraction). Baclofen acts to stimulate GABA receptors,
directly effecting muscle tone and spasticity. Oral baclofen
crosses the blood–brain barrier poorly, preventing its effective entrance into the CNS. When delivered intrathecally, its
cerebrospinal fluid concentrations are a hundredfold greater
than those obtained by oral ingestion. Intrathecal baclofen
has fewer systemic side effects compared to oral baclofen.
However, the procedure does include additional surgical risks
and possible complications.34 Evidence supports the efficacy
of ITB, and indicates greatest efficacy in people with severe
spasticity. ITB helps to reduce pain, improve sleep, improve
daily living activities, improve abilities, and enhance quality
of life.15 ITB is now a commonly practiced therapy, which
reduces spasticity in people who have CP, and has been proven
effective by multiple studies.35

Treatment practices
After agreeing on treatment goals with the person and caregivers involved, the use of our treatment algorithm is based
upon the degree of body involvement and the cognitive level
of the person.
Persons with spasticity limited primarily to muscle groups
in one limb are excellent candidates for neuromuscular
blockade with botulinum toxin, phenol or a combination
of the two. In patients with selective motor control, we are
more aggressive, with repeat injections accompanied by
physical therapy, bracing, electrical stimulation, and other
supportive modalities. Injections should be continued on a
regular basis at three to four times per year.33 Unsuccessful
trials should lead to pursuing treatments similar to those for
generalized spasticity. People commonly encountered in this
group include individuals afflicted by stroke and hemiplegic
or diplegic cerebral palsy. Neuromuscular blockade can
be utilized as an adjunctive therapy, alongside intrathecal
baclofen therapy, SDR, and musculoskeletal surgery.
Treating generalized spasticity is more complex. Oral
medication is commonly used as an initial form of treatment.
However, due to commonly encountered sedation, this can be
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counterproductive for participation in physical, occupational,
and speech therapies, as well as for cognitive development.
For people with severe impairments, demonstrating an
absence of cognitive development, the level of sedation that
often accompanies oral medications may be acceptable and/or
desirable. This scenario is commonly encountered in spastic
quadriparetic CP and TBI. Care must be exercised following
TBI, as sedation may mask cognitive recovery.
ITB therapy is considered in individuals with generalized spasticity, with intact or developing cognition, and/or
who fail oral medications.36 While the use of ITB therapy to
treat spasticity is becoming more commonly practiced, it is
often overlooked. ITB therapy has been the most universally
studied option for the treatment of spasticity related to CP.
Less research has been done to indicate ITB’s significance
for people with other underlying injuries and diseases of
the CNS, such as CVA, TBI, MS, and SCI. For example, an
estimated 17%–42.6% of CVA survivors experience spasticity, but less than 1% of those who experience a disabling
form of spasticity receive ITB treatment.37 The original
labeling of baclofen suggested waiting one year after SCI,
and 6 months following CVA. Our anecdotal experience is
that earlier treatment may avoid many of the musculoskeletal
complications of spasticity. This has been demonstrated (in
the orthopedic literature) in patients with cerebral palsy.38
Ongoing trials are underway to help clarify this issue. This
therapy can be considered in growing, and adult, patients with
di-, hemi- or quadriparetic CP, TBI, MS, or SCI, regardless
of cognitive status.
Nonpharmacological treatments are important adjuncts
when treating spasticity, whether it is generalized or focal
(Figure 2). Nonpharmacological approaches include occupational therapy, physiotherapy, orthotics, casting, or a
combination of these methods. Strength training is imperative
to help restore muscle balance. Muscle balance allows normal muscle, bone, and joint development and maintenance.
Achieving strength is a key component in reaching normal
function. There are many variables responsible for restoring
muscle balance beyond the physiologic ability of muscle to
be strengthened. This is one of the more critical areas where
the IDAHO criteria can be useful in assessing the optimal
delivery of care.

Pediatric considerations
While CVA is the most common cause of spasticity in adults,
the most common causes in children are CP, TBI, and spinal
cord injury.39 There is a substantial difference in the impact of
spasticity on children, versus adults. In adults who experience
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Focal spasticity
Botulinum toxin trial
injection
Positive selective motor
control
Repeated intramuscular
injections

Negative selective motor
control
Generalized treatment

Generalized spasticity
Presence of cognitive
function
Intrathecal baclofen

Absence of cognitive
function
Oral baclofen

Figure 2 Treatment practice in focal and generalized spasticity.

spasticity, inherent muscle length is present, and there is
no deficiency in normal muscle length and architecture.
The effects of spasticity in children can be substantially
more devastating, due to the effects of muscle tightness on
the growing musculoskeletal system. Unlike bone, muscle
does not have a growth plate. Muscle growth is directed by
the tensile forces of the bone, pulling under physiological
loading as the bone elongates, which subsequently causes
relaxed muscles to stretch.28 Therefore, muscle grows at
the rate of bone growth. Children with CP are musculoskeletally normal at birth, with spasticity occurring during rapid
growth, preventing normal bone and muscle development.40
This muscle shortening can be substantial. In a comparative
study, longitudinal muscle growth was reduced by 45% in
spastic mice, compared with normal mice.41 This restricted
longitudinal muscle growth and increased tension of the
muscle can result in limb deformities, joint dislocations, and
poor motor function.42
There are many factors to consider when treating children
with spasticity. A study by Gorter et al found that spasticity
is only marginally related to gross motor function development in infants of less than 2 years of age who have CP,
and that other environmental or family factors may have a
much greater influence on gross motor function.42–44 Here,
again, it is important to account for factors other than direct
interventions, in considerations of functional gains. We know
that severe spasticity often inhibits motor activity, and that
treating this spasticity may promote development of motor
pathways, by allowing more movements.39 By aggressively
treating spasticity early, we may be preserving opportunity
for future gains.
Despite considerable costs, treating spasticity in children
has shown to be both cost-effective and beneficial. 45
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A study performed by Kan et al compared preoperative
and postoperative data, using MAS and GMFCS, for two
groups of children who received either ITB pumps or SDR.
The results 1 year post-treatment were decreased tone,
increased range of motion, and improved function, for both
ITB and SDR groups, showing both surgical treatments to be
efficacious for children with moderate to severe spasticity.
The benefits of these successful treatments continue. There
was a significant decrease in the number of subsequent
orthopedic procedures needed, and a parents’ satisfaction
rate of 95.8% with these treatments.1 Having an improved
range of motion and function not only improves quality of
life for the child, but also eases the burden of the parents in
providing proper care.
It has been observed that early treatment of spasticity
reduces the need for orthopedic surgery for contracture or
torsion deformity in children with severe spasticity from
CP.42,45 Eliminating tone allows children to strengthen
and achieve motor control, thereby preventing the
musculoskeletal ramifications of spasticity. Evaluating
functional improvement can be challenging. Though a
child may be improving, he or she may also be moving
away from the normal trajectory. For example, children
with diplegic CP generally experience improvements until
they reach age six, at which point function often plateaus
or declines. Up until this time, spasticity can substitute for
underlying weakness. However, as they mature skeletally
and gain weight, spasticity becomes a poor surrogate for
normal muscular balance and strength. This can be explained
by a power (strength) to weight ratio; young children have
a high power to weight ratio. However, as children age,
their mass begins to increase more rapidly in proportion
to their physical strength, resulting in a reversal: to a low
power to weight ratio. We must be diligent in avoiding the
preservation of spasticity for this deceptive “function,” while
it impairs normal musculoskeletal development.

Conclusion
It is well-established that oral, intramuscular, and intrathecal medications are effective in decreasing spasticity. The
management of severe spasticity in order to improve function,
however, involves a complex web of intervening variables,
including infrastructure, desire and motivation to make lifestyle changes, ability remaining following injury, hospital
access to appropriate care, and opportunity. Spasticity is the
critical impediment that must be removed for individuals
striving to reach higher function, or to improve the care and
comfort of those with severe cognitive impairment.
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